Oncolytics Biotech Inc SEC filings ONCY
Oncolytics Biotech Inc has 1,000 filings in SEC EDGAR's recent list, going back to Jan 31, 2008. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 8, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 6, 2026 | — |
| 424B5 | Prospectus supplement | Apr 6, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| F-10POS | Filing | Apr 1, 2026 | — |
| S-8 POS | Filing | Apr 1, 2026 | — |
| S-8 POS | Filing | Apr 1, 2026 | — |
| POS AM | Filing | Apr 1, 2026 | — |
| S-3 | Shelf registration | Apr 1, 2026 | — |
| S-8 | Employee stock plan registration | Apr 1, 2026 | — |
| 424B3 | Prospectus | Dec 9, 2025 | — |
| F-4/A | Filing | Dec 5, 2025 | — |
| F-4 | Filing | Oct 20, 2025 | — |
| 424B5 | Prospectus supplement | Oct 17, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 22, 2025 | — |
| F-X | Form f-x | Jul 25, 2024 | — |
| F-10 | Form f-10 | Jul 25, 2024 | — |
| S-8 | Employee stock plan registration | Jun 4, 2024 | — |
| F-10/A | Filing | Jun 16, 2022 | — |
| F-X | Form f-x | Jun 10, 2022 | — |
| F-10 | Form f-10 | Jun 10, 2022 | — |
| F-10/A | Filing | Jun 12, 2020 | — |
| F-X | Filing | Jun 8, 2020 | — |
| F-10 | Filing | Jun 8, 2020 | — |
| F-10/A | Filing | May 4, 2018 | — |
| F-X | Filing | Apr 25, 2018 | — |
| F-10 | Filing | Apr 25, 2018 | — |
| S-8 | Employee stock plan registration | Jul 17, 2015 | — |
| F-10/A | Form f-10/a | Aug 1, 2014 | — |
| F-X | Form f-x | Jul 25, 2014 | — |
| F-10 | Form f-10 | Jul 25, 2014 | — |
| F-10/A | Filing | Jul 3, 2012 | — |
| F-X | Filing | Jun 21, 2012 | — |
| F-10 | Filing | Jun 21, 2012 | — |
| S-8 | Employee stock plan registration | Jan 10, 2011 | — |
| F-10/A | Filing | Jun 10, 2010 | — |
| F-X | Filing | Jun 2, 2010 | — |
| F-10 | Filing | Jun 2, 2010 | — |
| F-10/A | Amendment no. 1 to form f-10 | Jun 17, 2008 | — |
| F-X | Form f-x | Jun 6, 2008 | — |
| F-10 | Form f-10 | Jun 6, 2008 | — |
Showing 67 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1129928
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.